Atorvastatin Sensitizes Breast and Lung Cancer Cells to Ionizing Radiation. 2020

Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

Tumour cells may be resistant to radiotherapy that results in unsuccessful cancer treatment in patients. The aim of this study was to evaluate the sensitizing effect of atorvastatin (ATV) on breast cancer (MDA-MB-231) and non-small cell lung cancer (A-549) cells following exposure to ionizing radiation (IR). These cells were treated with ATV and exposed to X-ray at dose 4 Gy. The radiosensitizing effects of ATV were evaluated by flow cytometry and anti-proliferation assays. The production of reactive oxygen species (ROS) was determined in irradiated and treated cells with ATV. The findings of this study showed that ATV increased the percentage of apoptotic cells in irradiated breast and lung cancer cells. ATV exhibited anti-proliferative effect on cancer cells and increased cell death induced by IR. ATV increased ROS production in irradiated cells. The present study demonstrates that ATV has radiosensitizing effect on breast and lung cancer cells through increasing apoptosis, ROS production and cell death induced by IR.

UI MeSH Term Description Entries

Related Publications

Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
January 2005, Breast cancer research : BCR,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
November 2011, Radiation oncology (London, England),
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
April 2013, Pharmaceutical research,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
October 2007, Acta pharmacologica Sinica,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
January 2006, Cancer gene therapy,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
November 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
January 2022, BioMed research international,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
January 2015, The Prostate,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
January 2014, General physiology and biophysics,
Seyed Jalal Hosseinimehr, and Fatemeh Ghasemi, and Farzaneh Flahatgar, and Najmeh Rahmanian, and Arash Ghasemi, and Hossein Asgarian-Omran
January 2014, Breast cancer research and treatment,
Copied contents to your clipboard!